8-K
filed February 1, 2023, 6:59 PM ET
ticker CTVA
CIK 0001755672
earnings
confidence high
sentiment positive
materiality 0.70
Corteva reports FY2022 operating EPS $2.67, net sales $17.46B; guides FY2023 operating EPS $2.70-$2.90
Corteva, Inc.
2022-FY EPS reported
$1.58
revenue$17,455,000,000
- Q4 GAAP loss from continuing ops $41M, EPS -$0.06; operating EPS $0.16 (+100% YoY).
- FY2022 net sales $17.46B (+11% YoY), organic +15%; operating EBITDA $3.22B (+25%).
- Seed sales $8.98B (+7%), Crop Protection $8.48B (+17%); both segments saw price gains.
- 2023 guidance: net sales $18.1-18.4B, operating EBITDA $3.4-3.6B, operating EPS $2.70-$2.90.
- Acquisitions of Stoller and Symborg expected to close in first half 2023.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Corteva, Inc. reported Three months ended December 31, 2022 results: revenue $3.83B, net income $(41)M, EPS $(0.06).
- Period
- Three months ended December 31, 2022
- Revenue
- $3.83B
- Net income
- $(41)M
- EPS
- $(0.06)
- Result
- reported results
Exact text from the filing
4Q 2022 Results Overview Net Sales Loss from Cont. Ops (After Tax) EPS GAAP $3.83B $(41)M $(0.06)
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Corteva, Inc. reported Full year 2023 results: revenue $18.1 billion to $18.4 billion, EPS $2.70 to $2.90 per share. Guidance initiated.
- Period
- Full year 2023
- Revenue
- $18.1 billion to $18.4 billion
- EPS
- $2.70 to $2.90 per share
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
The Company provided full-year 2023 guidance3 and expects net sales in the range of $18.1 billion to $18.4 billion. Operating EBITDA1 is expected to be in the range of $3.4 billion to $3.6 billion. Operating EPS1 is expected to be in the range of $2.70 to $2.90 per share.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.